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Case Report
Introduction
Coronary slow-flow phenomenon (CSFP), also known as car-
diac syndrome Y, is characterized angiographically by delayed 
distal vessel opacification in the absence of obstructive coro-
nary artery disease and represents a pathology related to under-
lying dysfunction of microvascular resistance.1 The diagnosis 
of CSFP is made via coronary angiography based on either a 
reduced Thrombolysis in Myocardial Infarction (TIMI) flow 
grade of 2 or increased corrected TIMI frame count of greater 
than 27 frames in one or more epicardial vessel.2,3
The prevalence of CSFP has been reported to range 
between 1% and 5% of diagnostic coronary angiograms and 
is classically described in young male smokers with recur-
rent chest pain.2,4,5 Regarding the coronary vasculature, the 
left anterior descending (LAD) artery, even when corrected 
for length, is most often involved (50% to 90% of the time), 
followed by the right coronary artery (28% to 45%) and the 
left circumflex (-20%).6,7 Coronary angiograms in patients 
with CSFP are often referred to as “normal” or “mild 
nonobstructive disease,” which lends itself into classifying 
these phenotypical patients as having “chest pain with a neg-
ative cardiac catheterization.” Perhaps due to the lack of a 
fully understood pathophysiology, CSFP is frequently not 
identified as a root cause of abnormal ischemic testing and 
recurrent chest pain symptoms.
Various medications have been evaluated for the treat-
ment of CSFP. However, the actual efficacies of the majority 
of these pharmacological agents have not been established. 
Oral calcium channel blockers (CCBs) can attenuate the 
microvascular effects associated with coronary slow-flow.8 
Studies have utilized intracoronary (IC) CCBs to improve 
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Abstract
Background. Coronary slow-flow phenomenon (CSFP) is characterized by delayed distal vessel opacification of contrast, 
in the absence of significant epicardial coronary stenosis. CSFP has been reported as a cause of chest pain and abnormal 
noninvasive ischemic tests and is often underrecognized. Material and Methods. Charts and angiographic records from our 
institution were reviewed to identify 15 consecutive patients who were diagnosed with CSFP from January 2016 to January 
2017. Results. Of the 15 patients (4 females and 11 males) studied, the mean age was 59.1 years (range = 45-86 years); 
all had left ventricular ejection fraction >45% and without significant valvular stenosis/regurgitation. The indication for 
coronary angiography for all 15 patients was chest pain with abnormal noninvasive tests. Of the 11 patients who underwent 
previous coronary angiograms, all revealed prior evidence of CSFP. None of these patients were on calcium channel blockers 
(CCBs) or long-acting nitroglycerin agents before angiography. Intracoronary CCBs were effectively utilized to alleviate the 
angiographic finding (improvement in Thrombolysis in Myocardial Infarction frame count) in all 15 patients. Oral CCBs were 
started with subsequent improvement in all 15 patients (mean follow-up time = 13.6 months). Conclusion. Coronary slow-flow 
should be a diagnostic consideration in patients presenting with chest pain and abnormal noninvasive ischemic testing with 
nonobstructive epicardial vessels. CSFP remains underrecognized, and the specific standard of care for treatment has not 
been established. In each of the 15 cases, intracoronary nifedipine resolved the angiographic manifestation of coronary slow-
flow. Furthermore, in follow-up, all patients improved symptomatically from their chest pain after oral CCBs were initiated.
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the TIMI frame count in patients with CSFP on catheteriza-
tion. To our knowledge, however, no previous studies have 
uniformly evaluated the subsequent use of oral CCBs in 
patients whose angiographic slow-flow resolved with IC 
CCBs.9-11
We, therefore, reviewed 15 consecutive patients who 
were diagnosed with CSFP via the TIMI frame count method 
after IC administration of nifedipine. Our study focuses on 
the role of CCBs in alleviating this angiographic condition as 
well as its potential applicability for symptomatic treatment.
Material and Methods
Charts and angiographic records from our institution were 
reviewed of 15 consecutive patients who were diagnosed 
with CSFP from January 2016 to January 2017. Angiograms 
were evaluated and reviewed, and TIMI frame counts were 
verified. Slow-flow was defined by a frame count greater 
than 27 for all vessels (for the LAD, the frame count was 
divided by 1.7 to correct for the longer vessel length), 
which was a definition adapted from the previous method-
ology from Gibson et al.3 Coronary angiograms were per-
formed using power contrast injection Medrad Avanta, 
utilizing a standard flow rate of 4 mL/s, volume of 4 mL, 
and pressure limit of 450 PSI (pounds per square inch). Of 
note, cine fluoroscopy in our institution was acquired at 15 
frames per second, and therefore, the recorded frame count 
was multiplied by 2. Furthermore, all subjects had TIMI-2 
flow, which is defined by ≥3 beats to opacify prespecified 
branch points in the distal vasculature.2 Eleven of the 15 
patients had previous angiograms (spanning 2008-2014), 
which were obtained and reviewed. Four of the 15 patients 
never had previous coronary angiography (see Figures 
1-3).
Results
The diagnosis of CSFP was established in 15 patients by an 
initial corrected TIMI frame count >27 frames (mean of 
105 frames in vessels affected by CSFP), with improve-
ment to <27 frames after administration of IC nifedipine 
(average dose = 200 µg). Of the 15 patients (4 females and 
11 males) studied, the mean age was 59.1 years (range = 
45-86 years; Table 1); all had left ventricular ejection frac-
tion >45% (Table 2). The indication for coronary angiogra-
phy for all 15 patients was chest pain with abnormal 
noninvasive tests; 11 pharmacologic nuclear stress tests, 2 
stress echocardiograms, and 2 exercise-electrocardiogra-
phy stress tests. Thirteen (86%) patients had CSFP in the 
coronary distribution implied by the noninvasive testing. 
Of the 11 patients who underwent previous catheterization, 
all 11 had prior evidence of CSFP on previous angiogram. 
None of these patients were on CCBs or long-acting nitro-
glycerin agents before angiography (Table 3). Oral CCBs 
were started with subsequent improvement in all 15 patients 
(mean follow-up time = 13.6 months). The New York Heart 
Association anginal class was not assessed; however, 
patients reported a significant reduction in the frequency of 
their anginal episodes. The patients were assessed on an 
outpatient office visit follow-up.
Figure 1. Coronary slow-flow in both the left anterior 
descending (LAD) and left circumflex (LCX). Coronary angiogram 
at the 25th cine frame (utilizing 30 frames per second acquisition) 
revealing contrast opacification only up to the mid-vessel segment 
of the LAD and LCX.
Figure 2. It took 110 frames for the contrast to reach the distal 
vessel segment of the left anterior descending and left circumflex; 
significant contrast “washout” is noted with delayed or “sluggish” 
contrast filling.
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Discussion
CSFP, or cardiac syndrome Y, has distinct differences from 
cardiac syndrome X, one of which is that CSFP is defined by 
delayed opacification of contrast in the coronary vasculature 
during coronary angiography.5,12 CSFP is more often encoun-
tered in male smokers with metabolic syndrome.13 Our 
cohort is consistent with those prior reports, as 73.3% of our 
patients were male (mean age of 59.1 years) with 10 of the 15 
patients admitting to either active or former tobacco use. The 
average body mass index of the cohort was 31.3 kg/m2, with 
13 of the 15 patients having dyslipidemia.
Diagnosis of CSFP is made angiographically with demon-
stration of either TIMI-2 flow (ie, requiring ≥3 beats to 
opacify the vessel) or a corrected TIMI frame count of >27 
frames, which have been proposed by Beltrame et al2 in addi-
tion to no angiographic lesions ≥40% and delayed distal ves-
sel opacification in at least one epicardial vessel. Our patients 
were diagnosed based on the TIMI frame count and had an 
initial corrected TIMI frame count with a mean of 105 frames 
in vessels affected by slow-flow, with improvement to less 
than 27 frames after IC injection of nifedipine. Based on this 
positive IC response to nifedipine, oral CCBs were subse-
quently started in all 15 patients with significant symptom-
atic improvement in a 13.6-month follow-up.
Exclusion of alternate mechanisms of delayed coronary 
contrast progression is necessary to define CSFP, including 
coronary artery disease, coronary artery spasm, distal embo-
lization, no-reflow as a consequence of coronary interven-
tion, and coronary artery ectasia causing turbulent nonlaminar 
blood flow.14 Other exclusions include left ventricular myo-
cardial dysfunction, severe hypotension, sudden increases in 
intracavitary pressure, valvular heart disease, air embolism, 
or connective tissue disorders.6,15
The exact etiology and pathogenesis of CSFP is not defin-
itively established; however, microvascular dysfunction is 
highly suspected. Left and right ventricular myocardial 
biopsy specimens from patients with CSFP have demon-
strated the presence of coronary microvascular disease.6 
Small vessel disease, cell edema, capillary damage, subclini-
cal atherosclerosis, inflammation, fibromuscular hypertro-
phy, and degeneration of endothelial cells with resultant 
microvascular luminal narrowing have been reported as 
Table 1. Baseline Characteristics.
Variables Slow-Flow (n = 15)
Demographics
 Age (mean years) 59.1
 Male (%) 73.3%
 Female (%) 26.7%
Comorbidities
 Hypertension (%) 86.6%
 Diabetes (%) 20%
 Hyperlipidemia (%) 86.6%
 Body mass index (mean) 31.3
 Tobacco use (%) 66.6%
 No cocaine use (%) 6.6%
Table 2. Cardiac Findings.
Variables Slow-Flow (n = 15)
LVEF (%) 58%
Resting ST-T EKG changes (%) 20%
ACS on presentation (%) 6.6%
CSF in LAD (%) 86.6%
CSF in the LCX (%) 20%
CSF in the RCA (%) 46.6%
CSF in 2 or more epicardial 
vessels (%)
46.6%
Abbreviations: LVEF, left ventricular ejection fraction; ST-T EKG, 
segment-T electrocardiography; ACS, acute coronary syndrome; CSF, 
coronary slow-flow; LAD, left anterior descending; LCX, left circumflex; 
RCA, right coronary artery.
Table 3. Medication Use Prior to Diagnosis.
Medication Slow-Flow
Calcium channel blocker (%) 0%
Beta-blocker (%) 66.6%
Statin (%) 46.6%
Aspirin (%) 66.6%
ACE (angiotensin-converting enzyme) inhibitor (%) 26.6%
Long-acting nitroglycerin (%) 0%
Figure 3. Coronary angiogram after administration of 
intracoronary nicardipine, brisk vessel opacification by the 25th 
cine frame is noted, indicating resolution of coronary slow-flow.
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existing in association with CSFP.6,16-18 On the molecular 
level, endothelin-1 and neuropeptide Y (another reason for 
the label “syndrome Y”) have been implicated as possible 
mediators of the microvascular constriction response.6
In contemporary clinical practice, the majority of indi-
viduals who undergo catheterization do so after an abnormal 
noninvasive test. Ciavolella et al19 reported that 69% of their 
53-patient cohort with slow-flow had functional and perfu-
sion abnormalities that matched the coronary territories that 
demonstrated the delayed contrast dye run-off. Similarly, we 
report that 13 of the 15 (86.6%) patients of our cohort had 
CSFP in the vascular territory affected by noninvasive test-
ing. Hence, CSFP should be recognized as a cause of an 
abnormal ischemic evaluation.
On an in-depth review of our cohort’s medical record, it 
was noted that 11 of the 15 patients had indeed undergone 
previous coronary angiography. Each of these 11 patients 
had previously reported chest pains and had a subsequent 
abnormal noninvasive testing that led to the angiogram. 
These prior angiograms were obtained and interestingly 
also revealed CSFP. In fact, the most striking example 
were 3 patients in our cohort who underwent 3 diagnostic 
angiograms over a 5-year period of time. This, therefore, 
highlights the notion that the disease entity of CSFP is 
underrecognized in the community medical setting and 
that assigning the appropriate diagnosis may prevent addi-
tional testing.
Many pharmacologic agents have been studied in the 
treatment of CSFP. Studies have reported increased benefit 
with dipyridamole (a platelet cAMP-phosphodiesterase 
inhibitor) by decreasing the microvascular tone, statins via 
anti-inflammatory properties, angiotensin-converting 
enzyme inhibitors by directly modulating coronary micro-
vascular tone, and α-blockers by decreasing sympathetic 
activity, thus potentially reducing microvascular tone and 
improving microvascular perfusion.12,16,20-23 Larger scale 
studies have not shown any real efficacy of alpha channel 
blocker, cAMP-phosphodiesterase inhibitors, statins, and 
angiotensin-converting enzyme inhibitors in improving 
patients’ symptoms.12,24,25 Nonpharmacologic methods have 
been reported for symptom relief in this patient population 
including exercise training, transcendental meditation, cog-
nitive behavioral therapy, and transcutaneous electrical nerve 
stimulation.17,26
Of all classes of therapeutic medications that have been 
studied, CCBs appear to have the most efficacious role in 
attenuating the microvascular dysfunction associated with 
CSFP.6,8,27 A randomized double-blinded study of 80 patients 
by Li et al found that the oral CCB diltiazem alleviated 
angina, improved TIMI frame count, exercise tolerance with 
lessened ischemic electrocardiography response, and coro-
nary blood flow velocity.8 Chang et al11 found that IC vera-
pamil resulted in a significant slow-flow improvement in 
comparison with nitroglycerin.
A limitation to this report stems primarily from being a 
small study at a single center. However, this data set is from 
15 consecutive patients of CSFP, and all patients were man-
aged at the time of angiography and post-procedurally in a 
uniform manner. Second, there was no objective quantifica-
tion such as utilization of the Seattle Angina Questionnaire 
to measure patients’ perceived chest pain. Third, although 
there was sufficient follow-up time of 13.6 months, it 
remains to be seen if all oral CCBs (ie, dihydropyridines, 
phenylalkylamines, and benzothiazepines) are efficacious 
for CSFP, as different CCBs have varying properties. 
Finally, our study surprisingly did not have any patients who 
were already on CCBs and no patients had repeat angio-
grams while taking oral CCBs to determine if they were are 
as efficacious as IC CCBs. This is in comparison with the 
study by Li et al8 where repeat angiograms were performed 
while patients were on oral CCB therapy. It can be con-
cluded from this study, however, that IC CCB dramatically 
improved the angiographic finding of slow-flow and the ini-
tiation of oral CCBs in response to this angiographic finding 
appears promising.
Conclusion
Coronary slow-flow should be a diagnostic consideration in 
patients presenting with chest pain and abnormal noninva-
sive ischemic testing with normal or nonobstructive epicar-
dial vessels. Our cohort illustrates 15 patients with CSFP, of 
which 11 patients had previous coronary angiograms without 
recognition of this disease entity. In each of the 15 cases, IC 
nifedipine resolved the angiographic manifestation of coro-
nary slow-flow. Furthermore, after a 13.6-month follow-up, 
all 15 patients improved symptomatically from their chest 
pain after oral CCBs were initiated.
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